Mental Health

The Pharmacy Times® Mental Health resource center provides a home where mental health experts and pharmacists can meet to learn about the latest clinical news from the field. With articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content, this is a one-stop shop for folks in both professions.

What can we help you find?

Study: Long-Term Medication for Schizophrenia is Safe

The researchers found that the likelihood of being hospitalized for a somatic disease was just as high during the periods when the patients were on antipsychotic drugs as when they were not; however, the differences in mortality were clear.

Health Care Providers Reminded About the Risk of HLH with Lamotrigine

Hemophagocytic lymphohistiocytosis (HLH) induced by lamotrigine was recently an active topic on social media, with users following a recent article that reported an Austin, Texas detective had died from the condition in 2018.

Drug Suicidality Risks in Younger Patients

Megan Maroney, PharmD, BCPP, clinical associate professor, Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey; clinical psychiatric pharmacist, Monmouth Medical Center, Long Branch, NJ, discusses the higher risk for potential adverse effects of suicidal ideation and behavior, and depression in younger patients.

Drug Receives FDA Approval for Schizophrenia Treatment

Officials with the FDA have approved Intra-Cellular Therapies’ lumateperone (Caplyta) for the treatment of schizophrenia in adults, according to the company.

Mental Health Watch: Cognitive Impairment Is Linked to Presence of Persistent HIV in CNS

Many individuals with HIV who are receiving antiretroviral therapy have viral genetic material in the cells of their cerebrospinal fluid, making them more likely to experience memory and concentration problems, according to the results of a new study.

FDA Grants Fast Track Designation to PH94B for Treatment of Social Anxiety Disorder

The FDA has granted Fast Track Designation for the development of PH94B (VistaGen Therapeutics), a neuroactive nasal spray for on-demand treatment of social anxiety disorder (SAD).

Pharmacists Managing Mental Health, Substance Use Disorder Impact Their Communities

In addition to handling issues such as depression, post-traumatic stress disorder, suicide screenings, and anxiety, many mental health pharmacists deal with typical metabolic conditions, such as hypertension and diabetes.

Exercise: Another Potential Option for Substance Abuse Disorder

Exercise improves psychological, behavioral, neurobiological, and overall health of patients.

Pharmacist Training in Suicide Awareness Can Save Lives

Suicide rates in the United States increased in nearly every state between 1999 and 2016. More than half of the states had a more than 30% rise in suicides during that period. In 2016, nearly 45,000 lives were lost to suicide.

Asenapine Approved as First Transdermal Patch for Treatment of Schizophrenia

Officials from the FDA have approved Noven Pharmaceuticals, Inc.’s asenapine (Secuado) transdermal system, which is the first-and-only transdermal patch for the treatment of adults with schizophrenia, according to the company.

Study Reveals Public Perceptions of Dangerousness and Mental Illness

A recent study has revealed that just under half of the US population fears random mass shootings and terrorist attacks.

Fast-Acting Nasal Spray An Option For Treatment-Resistant Depression

The Pacific Ketamine Institute is now offering esketamine nasal spray (Spravato, Johnson & Johnson) for the treatment of patients who don't respond well to traditional oral antidepressants. It is a prescription medication to be used alongside an oral antidepressant.¹

The Pharmacy Times® Mental Health specialty page serves as a hub for all clinical news and articles related to mental health conditions, including: anxiety, eating disorders, and, depression. The coverage includes breaking news coverage of therapies recently approved by the US Food and Drug Administration, key takeaways from the latest clinical trials, and notifications of updates to clinical guidelines for countless conditions.